论文部分内容阅读
人端粒酶逆转录酶(hTERT)是人端粒酶的催化亚单位,正常成熟组织中基本无表达,而在多数恶性肿瘤中高表达,而使其成为恶性肿瘤特异性疫苗免疫治疗的首选抗原。T细胞表位肽疫苗是用抗原的T细胞表位制备的疫苗,在肿瘤免疫治疗中有其独特的优势。hTERT的T细胞表位肽疫苗可诱导机体产生特异性免疫应答,在小鼠体内显示了抗肿瘤效应,并已进入人体试验阶段,显示出较好的应用前景。文中就hTERT的T细胞表位肽疫苗在恶性肿瘤中的免疫治疗的研究进展作一综述。
Human telomerase reverse transcriptase (hTERT), a catalytic subunit of human telomerase, has almost no expression in normal mature tissues and is highly expressed in most malignant tumors, making it the first choice antigen for immunotherapy of malignant tumor-specific vaccines . T Cell Epitope Peptide Vaccines are vaccines prepared using antigenic T cell epitopes and have unique advantages in tumor immunotherapy. T cell epitope peptide vaccine of hTERT can induce the body to produce specific immune response, which shows the anti-tumor effect in mice and has entered the human experimental stage, showing a good application prospect. The progress of immunotherapy of hTERT T cell epitope peptide vaccine in malignant tumors is reviewed.